仑伐替尼二线治疗经阿替利珠单抗联合贝伐珠单抗进展的晚期肝细胞癌:多中心单臂II期试验
该研究为多中心单臂II期试验,纳入50例一线阿替利珠单抗联合贝伐珠单抗(atezo-bev)进展的不可切除肝细胞癌患者,接受二线仑伐替尼治疗。中位无进展生存期5.4个月(95%CI 4.2-7.1),达到预设主要终点;中位总生存期9.8个月,客观缓解率14.0%,疾病控制率82.0%。常见不良事件为腹泻、甲状腺功能减退和厌食,≥3级不良事件发生率46.0%。
要点
- 二线仑伐替尼中位PFS 5.4个月,达到预设主要终点。
- 中位OS 9.8个月,ORR 14.0%,DCR 82.0%。
- ≥3级不良事件发生率46.0%,安全性可控。
核心结论
- 仑伐替尼在atezo-bev进展后的晚期肝细胞癌二线治疗中显示出有前景的疗效和可控的安全性。
研究设计与样本
- 研究者发起的多中心单臂II期试验(KCSG HB23-04),2023年8月至2024年5月从13个中心纳入50例一线atezo-bev进展的uHCC患者。
- 患者接受二线仑伐替尼12 mg或8 mg每日(根据体重),直至疾病进展或不可耐受毒性。
- 主要终点为无进展生存期,次要终点包括总生存期、客观缓解率、疾病控制率、缓解持续时间和安全性。
主要发现
- 中位年龄66岁,72%有病毒性病因,atezo-bev中位进展时间6.5个月。
- 中位随访12.6个月,中位PFS 5.4个月(95%CI 4.2-7.1),达到预设主要终点(>4.5个月)。
- 中位OS 9.8个月(95%CI 8.1-NR),ORR 14.0%,DCR 82.0%,中位缓解持续时间9.4个月。
- 生存结局根据仑伐替尼的客观缓解不同而不同,但与atezo-bev的进展时间或HCC病因无关。
- 最常见不良事件为腹泻(42.0%)、甲状腺功能减退(32.0%)和厌食(30.0%),≥3级不良事件发生率46.0%。
临床怎么用
- 对于一线atezo-bev进展的uHCC患者,仑伐替尼可作为二线治疗选择。
- 治疗期间需监测腹泻、甲状腺功能减退和厌食等不良事件。
局限性
- 单臂设计,无对照臂,样本量50例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Atezolizumab plus bevacizumab (atezo-bev) is the global standard first-line therapy for unresectable hepatocellular carcinoma (uHCC). However, most patients eventually experience disease progression and optimal second-line strategies after atezo-bev failure remain unclear. Prospective evidence supporting multikinase inhibitors in this context is limited. METHODS: This investigator-initiated, multicenter, single-arm study (KCSG HB23-04) enrolled 50 patients with uHCC who progressed after first-line atezo-bev across 13 sites between August 2023 and May 2024. Patients received second-line lenvatinib at 12 mg or 8 mg daily, depending on body weight, until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival. Secondary endpoints were overall survival, objective response rate, disease control rate, duration of response, and safety. RESULTS: Of the 50 patients enrolled, the median age was 66 years, and 72% had a viral etiology. The median time to progression with atezo-bev was 6.5 months. During a median follow-up of 12.6 months, the median progression-free survival was 5.4 months (95% CI 4.2-7.1) (>4.5 months), meeting the prespecified primary endpoint. Median overall survival was 9.8 months (95% CI 8.1-NR). The objective response rate was 14.0%, and the disease control rate was 82.0%. The median duration of response was 9.4 months. Survival outcomes were different according to the objective response with lenvatinib, but not by time to progression on atezo-bev or HCC etiology. The most common adverse events were diarrhea (42.0%), hypothyroidism (32.0%), and anorexia (30.0%). Grade ≥3 adverse events occurred in 46.0% of patients. CONCLUSIONS: Lenvatinib demonstrated promising efficacy and a manageable safety profile as a second-line treatment for patients with HCC progressing on atezo-bev. These findings offer prospective evidence supporting lenvatinib as a viable treatment option in the post-atezo-bev context. IMPACT AND IMPLICATIONS: This study provides the first prospective evidence for the use of lenvatinib as a second-line therapy for patients with unresectable hepatocellular carcinoma who have progressed after first-line atezo-bev treatment. The findings highlight the potential of lenvatinib as a viable therapeutic option in a clinical setting where few alternatives are available. The results are particularly important for healthcare professionals managing unresectable hepatocellular carcinoma, as they provide a robust framework for considering lenvatinib in second-line treatment protocols. Given the manageable safety profile, these findings could be translated into practical recommendations for clinical practice, offering physicians a treatment strategy to improve patient outcomes following atezo-bev failure while guiding future research into combination therapies and broader patient populations. CLINICAL TRIAL NUMBER: NCT06138769.
引用
- Kim HD, Sym SJ, Chon HJ, et al. Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. J Hepatol. 2025. PMID: 41038766. doi:10.1016/j.jhep.2025.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。